Get 40% Off
🤑 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool.See stock ideas

Top 5 Health Care Stocks That Could Blast Off This Month

Published 21/08/2023, 12:32
© Reuters.  Top 5 Health Care Stocks That Could Blast Off This Month

Benzinga - by Lisa Levin, Benzinga Editor. The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30.

Here’s the latest list of major oversold players in this sector, having an RSI near or below 30.

Cano Health, Inc. (NYSE: CANO)

  • Cano Health reported worse-than-expected second-quarter financial results, withdrew its guidance and said it is pursuing a sale process. The company’s stock has a 52-week low of $0.3440 .
  • RSI Value: 25.64
  • CANO Price Action: Shares of Cano Health fell 10.7% to close at $0.3703 on Friday.
Kezar Life Sciences, Inc.
  • Kezar Life Sciences reported a year-over-year decrease in second-quarter EPS results. It has a 52-week low of $1.27.
  • RSI Value: 23.71
  • KZR Price Action: Shares of Kezar Life Sciences fell 7.2% to close at $1.29 on Friday.
BioLife Solutions, Inc.
  • BioLife Solutions reported worse-than-expected second-quarter financial results. The company’s stock has a 52-week low of $10.76.
  • RSI Value: 22.74
  • BLFS Price Action: Shares of BioLife Solutions fell 6.3% to close at $10.81 on Friday.
Allakos Inc.
  • Allakos posted a narrower-than-expected quarterly loss. The company’s 52-week low is $2.97.
  • RSI Value: 29.59
  • ALLK Price Action: Shares of Allakos fell 6.2% to close at $3.10 on Friday.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .
Alaunos Therapeutics, Inc.
  • Alaunos Therapeutics announced second-quarter financial results, interim clinical data and the exploration of strategic alternatives. The company has a 52-week low of $0.12.
  • RSI Value: 18.51
  • TCRT Price Action: Shares of Alaunos Therapeutics fell 5.9% to close at $0.1234 on Friday.

Read More: Nordson Likely To Post Lower Q3 Earnings; Here's A Look At Recent Price Target Changes By The Most Accurate Analysts

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.